Cancer Monoclonal Antibodies Market Size Estimated to Reach USD 410.95 Billion by 2032
The global cancer monoclonal antibodies market size is estimated to reach around USD 410.95 billion by 2032, increasing from USD 89.06 billion in 2023.
The cancer monoclonal antibodies market size was valued at USD 75.14 billion in 2022 and is growing at a healthy CAGR of 18.52% from 2023 to 2032. North America led the global market with the major market share of 39% in 2022.
The North America cancer monoclonal antibodies market size was valued at USD 29.30 billion in 2022 and is projected to surpass around USD 160.27 billion by 2032, growing at a remarkable CAGR of 18.52% from 2023 to 2032.
The Europe cancer monoclonal antibodies market size accounted for USD 27.60 billion in 2023 and is anticipated to hit around USD 127.39 billion by 2032, growing at a remarkable CAGR of 18.52% from 2023 to 2032.
Monoclonal antibodies are derived from a single B-cell, are identical immunoglobulins, and recognize a distinctive binding site on the antigen. Targeted specificity due to unique epitopes gives these molecules a wide variety of diagnostic and therapeutic applications for several ailments. Presently, monoclonal antibodies cater to a plethora of conditions, including but not limited to cardiovascular diseases, autoimmune diseases, cancer, blood-based disorders, and infectious diseases.
Download the Sample Copy of Report@ https://www.precedenceresearch.com/sample/2981
Bacteria and viruses are recognized as foreign molecules by the immune system and form an antigen-antibody complex. They were dubbed immunocomplex, triggering an immune response to destroy the antigen. Likewise, damaged or abnormal cells, such as cancer cells, can be eliminated. The global cancer monoclonal antibodies market has major stakes in the management and treatment of cancer.
Here, therapies involving monoclonal antibodies are designed to locate and bind to specific proteins found in cancer cells. These treatment alternatives are categorized as a type of immunotherapy as they subject the target cell to an immune response. During chemotherapies, these drugs can provide a variety of functions, such as immune system support, direct delivery aid, and cancer cell signal blockers.
Researchers associated with the cancer community globally concentrate a major portion of their efforts on the development of these laboratory-made monoclonal antibodies to mimic the functions of natural antibodies. These lab-synthesized structures can be created to target specific kinds of cancers and are primarily derived from four different cell origins: murine, humanized, chimeric, and human. Based on types, the market is segmented into naked antibodies and conjugated antibodies. Naked monoclonal antibodies are generally considered a single treatment, while the latter are attached antibodies for more precise therapies and are often combined with other drugs, radiation, and chemotherapies.
- In 2022, the humanised segment accounted for almost 41% of the revenue share.
- In 2022, the blood cancer segment contributed over 25% of the revenue share.
- Between 2023 and 2032, the trastuzumab (Herceptin) category is anticipated to grow at the quickest rate.
- In 2022, the hospitals category had the largest market share, accounting for 41%.
Personalized your customization here: https://www.precedenceresearch.com/customization/2981
- There has been a gradual increase in the annual incidences of cancer worldwide and associated deaths. According to a paper published in the journal American Cancer Society, 2023 witnessed over 4 million new diagnoses of cancer and around 1.4 million related deaths in America alone. As the second largest cause of morbidities and deaths globally, cancer generates significant revenue in the healthcare and biotechnology sectors. Monoclonal antibodies is an essential segment of diagnosis and therapeutic in the cancer industry. A considerable number of monoclonal antibodies are prescribed for cancer treatment and provide several opportunities for additional revenue generation and overall market progression. Moreover, a comprehensive developmental pipeline with potential restoratives catering to a variety of other diseases contributes towards market expansion.
- Monoclonal antibodies are the preferred therapy alternative for oncologists worldwide. This is in part due to its high success rates and a limited number of side effects. Another prominent reason driving the market is the massive amount of conducted and ongoing research on monoclonal antibodies. In addition to the existing monoclonal antibodies, clinical trials on novel and more advanced varieties are now being carried out for various types of cancer. Their specificity presents an attractive opportunity for the treatment of cancer. Research and development in the field drive the market to a great extent.
- The growth of the monoclonal antibodies market and a robust emphasis on the research and development of naked monoclonal antibody-based therapies have a substantial impact on the global cancer monoclonal antibodies market. They provide highly effective drug therapy for complicated conditions. Companies also benefit significantly from state backing and lenient regulatory compliance to develop the monoclonal antibody business.
You can place an order or ask any questions, please feel free to contact at firstname.lastname@example.org | +1 650 460 3308
Cancer Monoclonal Antibodies Market Covered by Regions:
Global Cancer Monoclonal Antibodies Market Size
USD 89.06 billion in 2023
USD 410.95 billion by 2032
18.52% CAGR (2023-2032)
North America Cancer Monoclonal Antibodies Market Size
USD 34.73 billion in 2023
USD 160.27 billion by 2032
18.52% CAGR (2023-2032)
Europe Cancer Monoclonal Antibodies Market Size
USD 27.60 billion in 2023
USD 127.39 billion by 2032
18.52% CAGR (2023-2032)
Asia-Pacific Cancer Monoclonal Antibodies Market Size
USD 21.37 billion in 2023
USD 98.62 billion by 2032
18.52% CAGR (2023-2032)
LAMEA Cancer Monoclonal Antibodies Market Size
USD 5.34 billion in 2023
USD 24.65 billion by 2032
18.52% CAGR (2023-2032)
North America held a greater market share during the forecast period due to its advanced healthcare infrastructure, growing number of notable industry participants, rising cancer incidence, and rising public awareness of cutting-edge treatments. Monoclonal antibodies for cancer have become a subject of increasing knowledge and expertise for biotechnology and pharmaceutical businesses. One such example is the American Cancer Society, Inc. According to estimates, there will be approximately 1.9 million new cancer cases diagnosed and 609,360 cancer-related deaths in the US in 2022. Thus, the high cancer incidence rate in the area is anticipated to support market expansion.
However, the Asia Pacific market is expanding at a substantial compound annual growth rate (CAGR) over the course of the forecast period. This can be attributed to a number of factors, including the quickening pace at which major global players are attempting to gain traction in the emerging market, the rising cancer incidence in the area, the growing use of biosimilars, the expansion of regional and global partnerships among important organisations, and the rise in healthcare spending.
Cancer Monoclonal Antibodies Market Scope
18.52% from 2023 to 2032
Market Size in 2023
USD 89.06 Billion
Market Size by 2032
USD 410.95 Billion
2023 To 2032
By Type, By Application, By Monoclonal Antibody Therapies, and By End-user
North America, Europe, Asia-Pacific, Latin America and Middle East & Africa
Private investments and financial initiatives by federal or state agencies provide minor researchers and small startups opportunities to conduct academic research on monoclonal antibodies and cancer. Pharmaceutical giants often form strategic partnerships with fellow firms or ventures with minor companies for the development of the therapeutic to match the ongoing trends in the healthcare sector. These collaborations help companies in the cancer monoclonal antibody market explore new technologies and produce innovative products. The partners share their knowledge and expertise in order to gain a foothold or dominate the fiercely competitive industry.
Moreover, state incentives for academic research allow several communities to expand their knowledge and understanding without the pressure to produce a new drug or tool. This has the potential to create several opportunities in the future for the development of the cancer monoclonal antibody market.
The development of artificial intelligence (AI) and several related technologies have been prevalent in recent decades. Machine learning and AI-based innovations have greatly benefited almost every industry. The healthcare sector has also witnessed several developments due to these technological innovations. AI-guided drug discovery helps reduce the cost and time associated with the developmental process of a therapeutic in the product lifecycle, as well as helps accelerate the production and manufacturing process. Automation has major applications in the diagnostics field with its rapid results and reduced operator errors.
- Monoclonal Antibodies Market: The global monoclonal antibodies market size accounted for USD 201.63 billion in 2022 and is projected to hit around USD 634.64 billion by 2032, poised to grow at a CAGR of 12.2% over the forecast period from 2023 to 2032.
- Biosimilar Monoclonal Antibody Market: The global biosimilar monoclonal antibody market size was estimated at USD 8.6 billion in 2022 and it is projected to surpass around USD 69 billion by 2032, registering growth at a CAGR of 23.2% from 2023 to 2032.
- Research Antibodies Market: The global research antibodies market size reached USD 4 billion in 2022 and is expected to be worth around USD 6.54 billion by 2032, registering a CAGR of 5.04% from 2023 to 2032.
- In January 2023, Hematology-focused Disc Medicine announced its intentions to invest $10 million in monoclonal therapeutics developing company, Mabwell Therapeutics. Focussed on the treatment of blood cancer, Mabwell would capitalize on the resources of the pharmaceutical giant to develop and commercialize a comprehensive portfolio of monoclonal antibodies for the treatment and diagnosis of blood disorders.
- In July 2022, Next Cure publicized the progress of its Immunohistochemical assay. This highly effective tool would aid additional laboratory investigations of monoclonal antibodies and is to be manufactured as an adjuvant to the S15 Monoclonal Antibody used to detect irregular cytoplasmic domains in proteins.
- In July 2022, the FDA gave its approval for the resubmission of Toripalimab. Developed by Junshi Biosciences and Coherus this drug was prescribed as a treatment of nasopharyngeal cancer. It is an anti-PD 1 monoclonal antibody that intercepts the binding of PD-1 with its respective ligands.
Market Key Players:
- Amgen Inc
- Eli Lilly and Company
- Merck & Co., Inc
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Bristol Myers Squibb Co.
- GlaxoSmithKline plc
- Johnson & Johnson
- AstraZeneca plc
Founded in 1876, Eli Lilly and Company was named after the founder and pharmaceutical chemist, Colonel Eli Lilly. More than 145 years later, the American pharmaceutical today has established offices in 18 countries with commercial relations with approximately 125 nations. Headquartered in Indianapolis, Indiana, Eli Lilly is committed to serving its customers with its full potential. According to the company's 2022 financial report, it had a net income of 6,244.8 million US dollars.
The Merck Group, generally referred to as Merck, includes a complex network of around 250 facilities. This is a German multinational company that deals with science and technology and is headquartered in Darmstadt, Germany. With operations spread across 66 countries, Merck boasts a workforce of about 60,000 talented and hardworking employees. The group is divided into three primary segments: Healthcare, electronics, and life sciences. Merck operates in Europe, Asia, Oceania, Africa, and the Americas, with research and development centers in Darmstadt, Tokyo, Boston, and Beijing, as well as other minor facilities in Taiwan, Israel, France, South Korea, India, and the UK. Merck's 2022 report shared its financial earnings. Its net sales were 22,232 million euros, which is 12.9% higher than its 2019 sales of 19,687 million euros. The oncology revenue was found to be 1,683 million euros.
- Blood Cancer
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Liver Cancer
By Monoclonal Antibody Therapies
- Bevacizumab (Avastin)
- Rituximab (Rituxan)
- Trastuzumab (Herceptin)
- Cetuximab (Erbitux)
- Panitumumab (Vectibix)
- Other Monoclonal Antibody Therapies
- Research Institutes
- North America
- Latin America
- Middle East and Africa
Browse Table of Contents: https://www.precedenceresearch.com/table-of-content/2981
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2981
Unlocking Market Insights through Data Excellence
The "Precedence Statistics" flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today's dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
For Latest Update Follow Us: